In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
1876 News Items found
Despite Pressing Need, Memorial Sloan Kettering Survey Finds Most Americans Unlikely to Enroll in Clinical Trials

The lack of participation in clinical research may be the Achilles heel facing today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of MSK, only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. For more information or to schedule an interview, please contact [email protected].
A young female doctor in a white coat sits with an older male patient in an exam room
Finding
Uncertainties about Clinical Trials Keep Patients from Enrolling

Most people are aware of how important clinical trials for cancer are and how they can lead to lifesaving breakthroughs, but they’re also unlikely to participate in them.
A Hodgkin lymphoma survivor who received nivolumab as part of a clinical trial.
In the Clinic
Immunotherapy Drug Approved for Treatment of Hodgkin Lymphoma

The immunotherapy drug nivolumab is now approved for patients whose Hodgkin lymphoma has failed other treatments.
DNA molecules wrapped around histones
Feature
The Future of Cancer Research: Five Reasons for Optimism

Discover some of the most exciting research that Memorial Sloan Kettering scientists are pursuing in the fight against cancer.
author finds help for chemo brain
Feature
Is Chemo Brain Real?

Cancer treatments like chemotherapy may cause cognitive changes, which experts call “chemo brain.” Learn how Memorial Sloan Kettering experts help patients with this condition.
Vice President Joe Biden addressed members of the American Association for Cancer Research on Wednesday in New Orleans.
In the News
At #AACR16, Vice President Biden Unveils ‘Moonshot’ Goal: A Decade’s Worth of Progress in Five Years

The 2016 annual meeting of the American Association for Cancer Research (AACR) ended with a visit from the Vice President.
José Baselga
Announcement
News from #AACR16: Precision Medicine Progress, Turbocharged CARs, and Turning Up the Heat against Cancer

At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.
Dr. Joan Massagué, Sloan Kettering Institute Director received the Pezcoller Foundation-AACR International Award for Cancer Research and was named an AACR fellow at AACR16.
Announcement
News from #AACR16: Targeted Therapy Breakthrough, Improved Survival in Melanoma, and Benefits of Gut Bugs

Long-awaited results of clinical trials testing targeted drugs and immunotherapy combinations were on offer at the annual American Association for Cancer Research (AACR) conference.
Promising New Research at the 2016 AACR Annual Meeting

Memorial Sloan Kettering experts are available to comment on new research presented at the American Association for Cancer Research 2016 Annual Meeting including immunotherapy and CAR T cells, exercise oncology, precision medicine and more. For more information and to set up interviews or access photos, email Nicole H. McNamara at [email protected].
Woman diagnosed with lymphoma
Feature
Ready to Fight, but My Doctor Says to Wait: Watchful Waiting after a Lymphoma Diagnosis

The watch and wait approach to treatment, also called active surveillance, is common for lymphomas that pose no immediate threat to a patient’s health. But the tactic can leave some patients initially feeling anxious.